At a glance
- Originator Fujisawa
- Class Analgesics; Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 21 Jan 1997 New profile
- 21 Jan 1997 Preclinical development for Rheumatic disorders in Japan (PO)